XML 46 R33.htm IDEA: XBRL DOCUMENT v3.21.1
Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)
 3 Months Ended
Apr. 04, 2021
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Earning Per Share
The following presents the detailed calculation of EPS:
 Three Months Ended
(MILLIONS)April 4,
2021		March 29,
2020
EPS Numerator––Basic
Income from continuing operations attributable to Pfizer Inc.
$4,868 $2,474 
Less: Preferred stock dividends––net of tax
— — 
Income from continuing operations attributable to Pfizer Inc. common shareholders
4,868 2,474 
Income from discontinued operations––net of tax9 881 
Net income attributable to Pfizer Inc. common shareholders
$4,877 $3,354 
EPS Numerator––Diluted  
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions
$4,868 $2,474 
Income from discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions9 881 
Net income attributable to Pfizer Inc. common shareholders and assumed conversions
$4,877 $3,355 
EPS Denominator  
Weighted-average number of common shares outstanding––Basic
5,584 5,545 
Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements78 68 
Weighted-average number of common shares outstanding––Diluted
5,662 5,613 
Anti-dilutive common stock equivalents(a)
2 3 
(a)These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.